These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 33243967

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term results of induction chemotherapy for non-operable esophageal squamous cell carcinoma followed by concurrent chemoradiotherapy: a single-centre experience.
    Xiang G, Chai G, Lyu B, Li Z, Yin Y, Wang B, Pan Y, Shi M, Zhao L.
    Radiol Oncol; 2024 Sep 01; 58(3):444-457. PubMed ID: 39287163
    [Abstract] [Full Text] [Related]

  • 4. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
    Huang C, Zhu Y, Li Q, Zhang W, Liu H, Zhang W, Hu Y, Yuan Y, Liu M.
    Cancer Med; 2019 Jan 01; 8(1):28-39. PubMed ID: 30600600
    [Abstract] [Full Text] [Related]

  • 5. Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.
    Zhou XL, Zhu WG, Zhu ZJ, Wang WW, Deng X, Tao WJ, Ji FZ, Tong YS.
    Oncologist; 2019 Aug 01; 24(8):e677-e686. PubMed ID: 31040254
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM, Wu JL, Liufu WJ, Yu TT, Niu SQ, Bao Y, Peng F.
    Cancer Immunol Immunother; 2024 Feb 16; 73(3):55. PubMed ID: 38366287
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
    Yen YC, Chang JH, Lin WC, Chiou JF, Chang YC, Chang CL, Hsu HL, Chow JM, Yuan KS, Wu ATH, Wu SY.
    Cancer; 2017 Jun 01; 123(11):2043-2053. PubMed ID: 28152166
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Huang JQ, Liang HW, Liu Y, Chen L, Pei S, Yu BB, Pan XB.
    Front Immunol; 2024 Jun 01; 15():1355198. PubMed ID: 38550598
    [Abstract] [Full Text] [Related]

  • 12. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
    Lin WC, Ding YF, Hsu HL, Chang JH, Yuan KS, Wu ATH, Chow JM, Chang CL, Chen SU, Wu SY.
    Cancer; 2017 Oct 15; 123(20):3904-3915. PubMed ID: 28608916
    [Abstract] [Full Text] [Related]

  • 13. Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy.
    Chen YH, Lu HI, Chien CY, Lo CM, Wang YM, Chou SY, Su YY, Shih LH, Li SH.
    Sci Rep; 2017 Jan 30; 7():41785. PubMed ID: 28134308
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY, Hsu CP, Yeh HL, Chuang CY, Lin JF, Chang CF.
    Kaohsiung J Med Sci; 2018 May 30; 34(5):281-289. PubMed ID: 29699635
    [Abstract] [Full Text] [Related]

  • 17. Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers.
    Chen F, Luo H, Xing L, Liang N, Xie J, Zhang J.
    Thorac Cancer; 2018 Jan 30; 9(1):59-65. PubMed ID: 29024498
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
    Li J, Gong Y, Diao P, Huang Q, Wen Y, Lin B, Cai H, Tian H, He B, Ji L, Guo P, Miao J, Du X.
    Radiat Oncol; 2018 Jan 22; 13(1):12. PubMed ID: 29357883
    [Abstract] [Full Text] [Related]

  • 19. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W, Yu S, Zhang W, Xiao Z, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Gao S, Mao Y, Xue Q, Sun K, Liu X, Fang D, Li J, Wang D.
    BMC Cancer; 2020 Feb 18; 20(1):130. PubMed ID: 32070309
    [Abstract] [Full Text] [Related]

  • 20. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma.
    Ochi M, Murakami Y, Nishibuchi I, Kubo K, Imano N, Takeuchi Y, Kimura T, Hamai Y, Emi M, Okada M, Nagata Y.
    J Radiat Res; 2021 Jan 01; 62(1):142-148. PubMed ID: 33392619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.